Global Medicines Program

January 24, 2014

Launch of Bangladesh’s National Pharmacovigilance Program

Bangladesh_2013-030wframe-300x225

In September 2013 the Global Medicines Program, through the SIAPS program and other partners, participated in the official launch of the National Pharmacovigilance Program and the Guidelines for the National Pharmacovigilance and Medicine Information System in Bangladesh.  This event was the highlight of a 3-day workshop to launch the Program and the Guidelines, and included a training on pharmacovigilance and regulatory systems.

The launch was attended by Andy Stergachis, MSH staff, and special guests including Secretary of Ministry of Health & Family Welfare, DGDA, General Secretary of Bangladesh Association of Pharmaceutical Industries, and Director of Office of Population, Health, Nutrition and Education, USAID/Bangladesh.  Workshop participants included hospital managers from Dhaka-area hospitals and DGDA staff.

In 2012, the Global Medicines Program assisted the Bangladesh Directorate General of Drug Administration (DGDA) through SIAPS to conduct a comprehensive assessment of national medicines regulatory and pharmacovigilance system, followed by a dissemination workshop. See below.

_________________________________________________________________________________________________________

india_Bdesh_dubai_2012_078

On November 13-14, 2012, the Global Medicines Program participated in disseminating the results of an assessment of the pharmacovigilance and drug regulatory systems in Bangladesh.  The assessment was conducted in conjunction with Management Sciences for Health with funding from the U.S. FDA and USAID through the Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program.  The dissemination workshop held in Dhaka, Bangladesh, was attended by the country’s Senior Secretary of their Ministry of Health and Family Welfare and the head of their Directorate General of Drug Administration (DGDA), along with many of the staff of the DGDA.  The project is part of a multi-country assessment of pharmacovigilance systems in Asian countries.